Free Trial
NYSE:NAVB

Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis

Navidea Biopharmaceuticals logo
$0.0004 0.00 (0.00%)
As of 03/28/2025 12:49 PM Eastern

About Navidea Biopharmaceuticals Stock (NYSE:NAVB)

Key Stats

Today's Range
$0.0003
$0.0004
50-Day Range
N/A
52-Week Range
$0.00
$0.13
Volume
2,573 shs
Average Volume
10,370 shs
Market Capitalization
$40,033.60
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Remove Ads
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Stock News Headlines

While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits
While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.
SK Biopharmaceuticals Co. Ltd.
See More Headlines

NAVB Stock Analysis - Frequently Asked Questions

Navidea Biopharmaceuticals' stock was trading at $0.0001 on January 1st, 2025. Since then, NAVB shares have increased by 300.0% and is now trading at $0.0004.
View the best growth stocks for 2025 here
.

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.60 million.

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), CorMedix (CRMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), Advanced Micro Devices (AMD) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/10/2021
Today
3/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NAVB
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8,126.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
56,367,000
Market Cap
$40,033.60
Optionable
Optionable
Beta
1.87
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NYSE:NAVB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners